These findings not only elucidate a new mechanism of estrogen-induced multidrug resistance in breast cancer but also point to ERα36 as a potential therapeutic target, particularly in tumors that are ERα-negative but still responsive to estrogen at the membrane level. This evidence concerns the gene ESR1 and breast carcinoma.